149 related articles for article (PubMed ID: 37150609)
21. An Increase in the clinical isolation of acquired AmpC β-lactamase-producing Klebsiella pneumoniae in Korea from 2007 to 2010.
Park MJ; Kim TK; Song W; Kim JS; Kim HS; Lee J
Ann Lab Med; 2013 Sep; 33(5):353-5. PubMed ID: 24003426
[TBL] [Abstract][Full Text] [Related]
22. Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009.
Jean SS; Lee WS; Bai KJ; Yu KW; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
Diagn Microbiol Infect Dis; 2015 Apr; 81(4):290-5. PubMed ID: 25600841
[TBL] [Abstract][Full Text] [Related]
23. Emergence and prevalence of beta-lactamase-producing Klebsiella pneumoniae resistant to cephems in Japan.
Muratani T; Kobayashi T; Matsumoto T
Int J Antimicrob Agents; 2006 Jun; 27(6):491-9. PubMed ID: 16701983
[TBL] [Abstract][Full Text] [Related]
24. High prevalence of CTX-M-15 and first report of CTX-M-3, CTX-M-22, CTX-M-28 and plasmid-mediated AmpC beta-lactamase producing Enterobacteriaceae causing urinary tract infections in Bosnia and Herzegovina in hospital and community settings.
Ibrahimagić A; Bedenić B; Kamberović F; Uzunović S
J Infect Chemother; 2015 May; 21(5):363-9. PubMed ID: 25638292
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and characterization of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolated in Korean hospitals.
Ko KS; Lee MY; Song JH; Lee H; Jung DS; Jung SI; Kim SW; Chang HH; Yeom JS; Kim YS; Ki HK; Chung DR; Kwon KT; Peck KR; Lee NY
Diagn Microbiol Infect Dis; 2008 Aug; 61(4):453-9. PubMed ID: 18482815
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates.
Morrissey I; Bouchillon SK; Hackel M; Biedenbach DJ; Hawser S; Hoban D; Badal RE
J Med Microbiol; 2014 Apr; 63(Pt 4):556-561. PubMed ID: 24478449
[TBL] [Abstract][Full Text] [Related]
27. In vitro Activity of Cefmetazole and Flomoxef among Extended-Spectrum Beta-Lactamase producing Enterobacterales.
Iio K; Hagiya H; Higashionna T; Otsuka F
New Microbiol; 2024 Jan; 46(4):348-353. PubMed ID: 38252045
[TBL] [Abstract][Full Text] [Related]
28. Screening extended-spectrum beta-lactamase production in Enterobacter cloacae and Serratia marcescens using antibiogram-based methods.
Su PA; Wu LT; Cheng KC; Ko WC; Chuang YC; Yu WL
J Microbiol Immunol Infect; 2010 Feb; 43(1):26-34. PubMed ID: 20434120
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of the MicroScan NegCombo panel Type 44 for detection of extended-spectrum beta-lactamase among clinical isolates of Escherichia coli, Klebsiella species, and Proteus mirabilis].
Ko SY; Chung JW; Song AJ; Yoon NS; Sung H; Kim MN
Korean J Lab Med; 2009 Feb; 29(1):35-40. PubMed ID: 19262076
[TBL] [Abstract][Full Text] [Related]
30. Current status of extended spectrum β-lactamase-producing Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis in Okinawa prefecture, Japan.
Nakama R; Shingaki A; Miyazato H; Higa R; Nagamoto C; Hamamoto K; Ueda S; Hachiman T; Touma Y; Miyagi K; Kawahara R; Toyosato T; Hirai I
J Infect Chemother; 2016 May; 22(5):281-6. PubMed ID: 26898665
[TBL] [Abstract][Full Text] [Related]
31. Flomoxef showed excellent in vitro activity against clinically important gram-positive and gram-negative pathogens causing community- and hospital-associated infections.
Yang Q; Zhang H; Cheng J; Xu Z; Hou X; Xu Y
Diagn Microbiol Infect Dis; 2015 Apr; 81(4):269-74. PubMed ID: 25641126
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of extended-spectrum β-lactamases, AmpC, and carbapenemases in Proteus mirabilis clinical isolates.
Shaaban M; Elshaer SL; Abd El-Rahman OA
BMC Microbiol; 2022 Oct; 22(1):247. PubMed ID: 36221063
[TBL] [Abstract][Full Text] [Related]
33.
Yamashiro H; Kasamatsu Y; Anan N; Takemura M; Yamano Y
Antimicrob Agents Chemother; 2023 Sep; 67(9):e0025823. PubMed ID: 37610203
[TBL] [Abstract][Full Text] [Related]
34. Characterization of clinical isolates of Enterobacteriaceae from Italy by the BD Phoenix extended-spectrum beta-lactamase detection method.
Sanguinetti M; Posteraro B; Spanu T; Ciccaglione D; Romano L; Fiori B; Nicoletti G; Zanetti S; Fadda G
J Clin Microbiol; 2003 Apr; 41(4):1463-8. PubMed ID: 12682131
[TBL] [Abstract][Full Text] [Related]
35. Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.
Mendes RE; Rhomberg PR; Bell JM; Turnidge JD; Sader HS
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):415-25. PubMed ID: 19249175
[TBL] [Abstract][Full Text] [Related]
36. Molecular characterization of extended-spectrum beta-lactamases and its correlation with clinical laboratory standards institute interpretive criteria for disk diffusion susceptibility testing in enterobacteriaceae isolates in Thaialnd.
Tangkoskul T; Tiengrim S; Onsomang S; Pati N; Aswapokee N; Thamlikitkul V; Chayakulkeeree M
Southeast Asian J Trop Med Public Health; 2012 Nov; 43(6):1461-9. PubMed ID: 23413710
[TBL] [Abstract][Full Text] [Related]
37. Molecular characterization and antimicrobial susceptibility of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae isolates at a tertiary-care centre in Monterrey, Mexico.
Garza-González E; Mendoza Ibarra SI; Llaca-Díaz JM; Gonzalez GM
J Med Microbiol; 2011 Jan; 60(Pt 1):84-90. PubMed ID: 20930052
[TBL] [Abstract][Full Text] [Related]
38. Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
Jones CH; Tuckman M; Keeney D; Ruzin A; Bradford PA
Antimicrob Agents Chemother; 2009 Feb; 53(2):465-75. PubMed ID: 19015360
[TBL] [Abstract][Full Text] [Related]
39. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups.
Castanheira M; Farrell SE; Krause KM; Jones RN; Sader HS
Antimicrob Agents Chemother; 2014; 58(2):833-8. PubMed ID: 24247134
[TBL] [Abstract][Full Text] [Related]
40. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.
Castanheira M; Mills JC; Costello SE; Jones RN; Sader HS
Antimicrob Agents Chemother; 2015; 59(6):3509-17. PubMed ID: 25845862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
